Tumor Biology

, Volume 36, Issue 9, pp 7107–7119 | Cite as

Demethoxycurcumin was prior to temozolomide on inhibiting proliferation and induced apoptosis of glioblastoma stem cells

  • Lei ShiEmail author
  • Xifeng Fei
  • Zhimin WangEmail author
Research Article


Temozolomide (TMZ) is widely used for treating glioblastoma (GBM), which can effectively inhibit the GBM growth for some months; however, it still could not prevent the invariable recurrence of GBM. The existence of glioma stem cells (GSCs) was considered to be a key factor. But TMZ has poor effects on GSCs. Recently, demethoxycurcumin (DMC) has been shown to display anti-tumor activities in malignant gliomas. However, its effects and the potential mechanisms on GSCs were still unclear. Our study showed that DMC was prior to TMZ on resulting in a significant increase in GSC apoptosis and a marked inhibition of cell growth in vitro. And combined treatment of DMC and TMZ showed more significant anti-GSC effects. Further research into the underlying mechanism demonstrated that this novel combinatorial regimen leads to changes of multiple cell signaling pathways including reactive oxygen species (ROS) production and caspase-3 signaling mitochondria-related apoptosis activation as well as inactivation of JAK/STAT3 signaling pathway. Taken together, our data demonstrate that the anti-GSC effects of DMC are better than TMZ, and combined treatment of DMC and TMZ has much stronger effects on GSCs.


Temozolomide Demethoxycurcumin Glioblastoma stem cell Proliferation Apoptosis 



This work was supported by the China Natural Science Foundation (81000963 and 81370062), Jiangsu Province’s 333 Talent Program (BRA2011046), Jiangsu Province “six personnel peak” funded projects (2013-WSN-145/028), Jiangsu Province’s Natural Science Foundation (BK2012670), Medical Research Foundation by Jiangsu Province Health Department (YG201301 and Z201318), the Clinical Technology Development of Jiangsu University (JLY20120053), the Kunshan Social Development Foundation (KS1006, KS1009), and the Suzhou Social Development Foundation (SYS201063). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Conflicts of interest

All authors have declared the sources of research funding for this manuscript and have no financial or other contractual agreements that might cause (or be perceived as causes of) conflicts of interest.


  1. 1.
    Stupp R, Tonn JC, Brada M, Pentheroudakis G, ESMO Guidelines Working Group. High-grade malignant glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v190–3.CrossRefPubMedGoogle Scholar
  2. 2.
    Clarke MJ, Mulligan EA, Grogan PT, Mladek AC, Carlson BL, Schroeder MA, et al. Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines. Mol Cancer Ther. 2009;8(2):407–14.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Athanassiou H, Synodinou M, Maragoudakis E, Paraskevaidis M, Verigos C, Misailidou D, et al. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol. 2005;23(10):2372–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Vescovi AL, Galli R, Reynolds BA. Brain tumour stem cells. Nat Rev Cancer. 2006;6(6):425–36.CrossRefPubMedGoogle Scholar
  5. 5.
    Braine J, Herpin F. Molecular hydrogen beyond the optical edge of an isolated spiral galaxy. Nature. 2004;432(7015):369–71.CrossRefPubMedGoogle Scholar
  6. 6.
    Chen J, Fu X, Wan Y, Wang Z, Jiang D, Shi L. miR-125b inhibitor enhance the chemosensitivity of glioblastoma stem cells to temozolomide by targeting Bak1. Tumour Biol. 2014;35(7):6293–302.CrossRefPubMedGoogle Scholar
  7. 7.
    Ruby AJ, Kuttan G, Babu KD, Rajasekharan KN, Kuttan R. Anti-tumourand antioxidant activity of natural curcuminoids. Cancer Lett. 1995;94(1):79–83.CrossRefPubMedGoogle Scholar
  8. 8.
    Luthra PM, Kumar R, Prakash A. Demethoxycurcumin induces Bcl-2 mediated G2/M arrest and apoptosis in human glioma U87 cells. Biochem Biophys Res Commun. 2009;384(4):420–5.CrossRefPubMedGoogle Scholar
  9. 9.
    Darling JL. The in vitro biology of human brain tumors. In: Thomas DGT, editor. Neuro-oncology: primary malignant brain tumors. Baltimore: Johns Hopkins University Press; 1990. p. 1–25.Google Scholar
  10. 10.
    Shi L, Zhang J, Pan T, Zhou J, Gong W, Liu N, et al. MiR-125b is critical for the suppression of human U251 glioma stem cell proliferation. Brain Res. 2010;1312:120–6.CrossRefPubMedGoogle Scholar
  11. 11.
    Shi L, Chen J, Wang YY, Sun G, Liu JN, Zhang JX, et al. Gossypin induces G2/M arrest in human malignant glioma U251 cells by the activation of Chk1/Cdc25C pathway. Cell Mol Neurobiol. 2012;32(2):289–96.CrossRefPubMedGoogle Scholar
  12. 12.
    Zhang S, Wan Y, Pan T, Gu X, Qian C, Sun G, et al. MicroRNA-21 inhibitor sensitizes human glioblastoma U251 stem cells to chemotherapeutic drug temozolomide. J Mol Neurosci. 2012;47(2):346–56.CrossRefPubMedGoogle Scholar
  13. 13.
    Huang TY, Hsu CW, Chang WC, Wang MY, Wu JF, Hsu YC. Demethoxycurcumin retards cell growth and induces apoptosis in human brain malignant glioma GBM 8401 cells. Evid Based Complement Alternat Med. 2012;2012:396573.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Gong X, Schwartz PH, Linskey ME, Bota DA. Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy. Neurology. 2011;76(13):1126–34.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Narayan P, Mentzer Jr RM, Lasley RD. Annexin V staining during reperfusion detects cardiomyocytes with unique properties. Am J Physiol Heart Circ Physiol. 2001;281(5):H1931–7.PubMedGoogle Scholar
  16. 16.
    Sandur SK, Pandey MK, Sung B, Ahn KS, Murakami A, Sethi G, et al. Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. Carcinogenesis. 2007;28(8):1765–73.CrossRefPubMedGoogle Scholar
  17. 17.
    Lee JW, Hong HM, Kwon DD, Pae HO, Jeong HJ. Dimethoxycurcumin, a structural analogue of curcumin, induces apoptosis in human renal carcinoma caki cells through the production of reactive oxygen species, the release of cytochrome C, and the activation of caspase-3. Korean J Urol. 2010;51(12):870–8.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Oliva CR, Moellering DR, Gillespie GY, Griguer CE. Acquisition of chemoresistance in gliomas is associated with increased mitochondrial coupling and decreased ROS production. PLoS ONE. 2011;6(9):e24665.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Yu M, Zheng Y, Sun HX, Yu DJ. Inhibitory effects of enalaprilat on rat cardiac fibroblast proliferation via ROS/P38MAPK/TGF-β1 signaling pathway. Molecules. 2012;17(3):2738–51.CrossRefPubMedGoogle Scholar
  20. 20.
    Ravindran J, Prasad S, Aggarwal BB. Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? AAPS J. 2009;11(3):495–510.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Barré B, Avril S, Coqueret O. Opposite regulation of Myc and p21waf1 transcription by STAT3 proteins. J Biol Chem. 2003;278(5):2990–6.CrossRefPubMedGoogle Scholar
  22. 22.
    Zhong K, Song W, Wang Q, Wang C, Liu X, Chen D, et al. Murine myeloid dendritic cells that phagocytose apoptotic T cells inhibit the immune response via NO. PLoS ONE. 2012;7(11):e49378.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Ji JD, Kim HJ, Rho YH, Choi SJ, Lee YH, Cheon HJ, et al. Inhibition of IL-10-induced STAT3 activation by 15-deoxy-delta12,14-prostaglandin J2. Rheumatology (Oxford). 2005;44(8):983–8.CrossRefGoogle Scholar
  24. 24.
    Bojes HK, Suresh PK, Mills EM, Spitz DR, Sim JE, Kehrer JP. Bcl-2 and Bcl-xL in peroxide-resistant A549 and U87MG cells. Toxicol Sci. 1998;42(2):109–16.PubMedGoogle Scholar
  25. 25.
    Terrano DT, Upreti M, Chambers TC. Cyclin-dependent kinase 1-mediated Bcl-xL/Bcl-2 phosphorylation acts as a functional link coupling mitotic arrest and apoptosis. Mol Cell Biol. 2010;30(3):640–56.CrossRefPubMedGoogle Scholar
  26. 26.
    Shieh JM, Chen YC, Lin YC, Lin JN, Chen WC, Chen YY, et al. Demethoxycurcumin inhibits energy metabolic and oncogenic signaling pathways through AMPK activation in triple-negative breast cancer cells. J Agric Food Chem. 2013;61(26):6366–75.CrossRefPubMedGoogle Scholar
  27. 27.
    Ni X, Zhang A, Zhao Z, Shen Y, Wang S. Demethoxycurcumin inhibits cell proliferation, migration and invasion in prostate cancer cells. Oncol Rep. 2012;28(1):85–90.PubMedGoogle Scholar
  28. 28.
    Hsu YC, Weng HC, Lin S, Chien YW. Curcuminoids-cellular uptake by human primary colon cancer cells as quantitated by a sensitive HPLC assay and its relation with the inhibition of proliferation and apoptosis. J Agric Food Chem. 2007;55(20):8213–22.CrossRefPubMedGoogle Scholar
  29. 29.
    Selvendiran K, Koga H, Ueno T, Yoshida T, Maeyama M, Torimura T, et al. Luteolin promotes degradation in signal transducer and activator of transcription 3 in human hepatoma cells: an implication for the antitumor potential of flavonoids. Cancer Res. 2006;66(9):4826–34.CrossRefPubMedGoogle Scholar
  30. 30.
    Dayem AA, Choi HY, Kim JH, Cho SG. Role of oxidative stress in stem, cancer, and cancer stem cells. Cancers (Basel). 2010;2(2):859–84.CrossRefGoogle Scholar
  31. 31.
    Jiang JY, Sun Y, Yuan Y. Mechanism of temozolomide-induced anti-tumor effects on glioblastoma cells in vitro is via ROS-dependent SIRT1 signaling pathway. Zhonghua Zhong Liu Za Zhi. 2012;34(10):734–8.PubMedGoogle Scholar
  32. 32.
    Garrido C, Galluzzi L, Brunet M, Puig PE, Didelot C, Kroemer G. Mechanisms of cytochrome c release from mitochondria. Cell Death Differ. 2006;13(9):1423–33.CrossRefPubMedGoogle Scholar
  33. 33.
    Senft C, Polacin M, Priester M, Seifert V, Kögel D, Weissenberger J. The nontoxic natural compound curcumin exerts anti-proliferative, anti-migratory, and anti-invasive properties against malignant gliomas. BMC Cancer. 2010;10:491.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Shi L, Wan Y, Sun G, Zhang S, Wang Z, Zeng Y. miR-125b inhibitor may enhance the invasion-prevention activity of temozolomide in glioblastoma stem cells by targeting PIAS3. BioDrugs. 2014;28(1):41–54.CrossRefPubMedGoogle Scholar
  35. 35.
    Dauer DJ, Ferraro B, Song L, Yu B, Mora L, Buettner R, et al. Stat3 regulates genes common to both wound healing and cancer. Oncogene. 2005;24(21):3397–408.CrossRefPubMedGoogle Scholar
  36. 36.
    Rahaman SO, Harbor PC, Chernova O, Barnett GH, Vogelbaum MA, Haque SJ. Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene. 2002;21(55):8404–13.CrossRefPubMedGoogle Scholar
  37. 37.
    Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res. 2002;8(4):945–54.PubMedGoogle Scholar
  38. 38.
    Wang J, Wang H, Li Z, Wu Q, Lathia JD, McLendon RE, et al. c-Myc is required for maintenance of glioma cancer stem cells. PLoS ONE. 2008;3(11):e3769.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Zhou Z, Sun L, Wang Y, Wu Z, Geng J, Miu W, et al. Bone morphogenetic protein 4 inhibits cell proliferation and induces apoptosis in glioma stem cells. Cancer Biother Radiopharm. 2011;26(1):77–83.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Department of NeurosurgeryThe First People’s Hospital of Kunshan Affiliated with Jiangsu UniversitySuzhouChina
  2. 2.Department of NeurosurgerySuzhou Kowloon Hospital Affiliated with Shanghai Jiao Tong University School of MedicineSuzhouChina

Personalised recommendations